PMID- 36852793
OWN - NLM
STAT- MEDLINE
DCOM- 20230606
LR  - 20230612
IS  - 1875-5992 (Electronic)
IS  - 1871-5206 (Linking)
VI  - 23
IP  - 10
DP  - 2023
TI  - Erianin as a Promising Novel Agent in the Treatment of Neuroblastoma: The 
      Anticancer Effects and Underlying Molecular Mechanisms.
PG  - 1204-1210
LID - 10.2174/1871520623666230228095429 [doi]
AB  - BACKGROUND: Erianin is an active dibenzyl compound isolated from Dendrobium 
      officinale and Dendrobium chrysotoxum and there are very few studies on molecular 
      mechanisms and drug targets of erianin. In addition, there is no study 
      investigating the anti-cancer effect of erianin on neuroblastoma cells. 
      OBJECTIVE: The aim of the study is to investigate the anticancer effect of 
      erianin and the underlying mechanism of this effect on SH-SY5Y cells. METHODS: 
      The effects of erianin on cell viability, invasion and migration were determined 
      by XTT, matrigel chamber and wound healing evaluation, respectively. Expression 
      changes of miRNAs (microRNA) and apoptosis-related genes were evaluated by 
      RT-PCR, and the apoptosis rate was supported by Annexin V evaluation. RESULTS: 
      Erianin significantly decreased cell proliferation, invasion and migration. 
      Erianin administration caused apoptosis by significantly increasing caspase-7, 
      FADD (Fas-associated protein with death domain), BID (BH3 Interacting Domain 
      Death Agonist) and DR5 (Death receptor 5) gene expressions. While the rate of 
      total apoptotic cells was 45.35 +/- 6.80% in SH-SY5Y cells treated with erianin, it 
      was 0.133 +/- 0.05% in the control group (p = 0.000). In addition, erianin 
      administration significantly decreased the expressions of hsa-miR-155-5p (p = 
      0.014) and hsa-miR-223-3p (p = 0.004). Also, our study demonstrated for the first 
      time the relationship between erianin and mi-RNAs in a cancer cell. CONCLUSION: 
      Our study suggests that erianin may be a natural, safe and easily accessible drug 
      candidate that can be used in the treatment of neuroblastoma.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Kocoglu, Sema Serter
AU  - Kocoglu SS
AD  - Department of Histology and Embryology, School of Medicine, Balikesir University, 
      Balikesir, Turkey.
FAU - Secme, Mucahit
AU  - Secme M
AD  - Department of Medical Biology, School of Medicine, Ordu University, Ordu, Turkey.
FAU - Sunay, Fatma Bahar
AU  - Sunay FB
AD  - Department of Histology and Embryology, School of Medicine, Balikesir University, 
      Balikesir, Turkey.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Anticancer Agents Med Chem
JT  - Anti-cancer agents in medicinal chemistry
JID - 101265649
RN  - 0 (Erianin)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Humans
MH  - *Neuroblastoma/drug therapy
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Apoptosis
MH  - *MicroRNAs/genetics/therapeutic use
OTO - NOTNLM
OT  - Neuroblastoma
OT  - anticancer
OT  - apoptosis
OT  - cell viability
OT  - erianin
OT  - invasion
OT  - miRNAs
OT  - migration
EDAT- 2023/03/01 06:00
MHDA- 2023/06/06 06:42
CRDT- 2023/02/28 06:55
PHST- 2022/08/02 00:00 [received]
PHST- 2022/12/22 00:00 [revised]
PHST- 2022/12/22 00:00 [accepted]
PHST- 2023/06/06 06:42 [medline]
PHST- 2023/03/01 06:00 [pubmed]
PHST- 2023/02/28 06:55 [entrez]
AID - ACAMC-EPUB-129849 [pii]
AID - 10.2174/1871520623666230228095429 [doi]
PST - ppublish
SO  - Anticancer Agents Med Chem. 2023;23(10):1204-1210. doi: 
      10.2174/1871520623666230228095429.